Related references
Note: Only part of the references are listed.Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors
P. Schmid et al.
ANNALS OF ONCOLOGY (2010)
Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial
D. Arnold et al.
BRITISH JOURNAL OF CANCER (2009)
Safety and Efficacy of Patupilone in Patients With Advanced Ovarian, Primary Fallopian, or Primary Peritoneal Cancer: A Phase I, Open-Label, Dose-Escalation Study
Wim W. ten Bokkel Huinink et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
David S. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Improved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopilone
Jens Hoffmann et al.
CANCER RESEARCH (2008)
A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens
C. N. Krasner et al.
BRITISH JOURNAL OF CANCER (2007)
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy
Henri Roche et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Acetyl-l-carnitine for the treatment of chemotherapy-induced peripheral neuropathy - A short review
Domenico De Grandis
CNS DRUGS (2007)
Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers:: A Gynecologic Oncology Group study
Maurie Markman et al.
GYNECOLOGIC ONCOLOGY (2006)
Total synthesis and antitumor activity of ZK-EPO: The first fully synthetic epothilone in clinical development
Ulrich Klar et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2006)
Epithelial ovarian cancer: A review of current management
AE Guppy et al.
CLINICAL ONCOLOGY (2005)
Topotecan dosing guidelines in ovarian cancer: Reduction and management of hematologic toxicity
DK Armstrong
ONCOLOGIST (2004)
Pharmacological effects of formulation vehicles - Implications for cancer chemotherapy
AJ ten Tije et al.
CLINICAL PHARMACOKINETICS (2003)
Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation
H Gelderblom et al.
EUROPEAN JOURNAL OF CANCER (2001)
Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan
AN Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Share Paper
